Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED) (FUTURE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Immunogenicity and Safety of Quadrivalent HPV L1 Virus-Like Particle (VLP) Vaccine in 16- to 23-Year-Old Women When Administered Alone or Concomitantly With Hepatitis B Vaccine (Recombinant)--the F.U.T.U.R.E. Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
16 Years to 23 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Females age 16 to 23 years old
Must agree to refrain from sexual activity (vaginal or anal) for 48 hours prior to any scheduled visit
History of vaccination with an HPV vaccine
History of hepatitis B infection
History of vaccination with hepatitis B vaccine
History of genital warts or treatment for genital warts